NYSE:OGNPharmaceuticals
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit
Organon (NYSE:OGN) has entered an exclusive global licensing agreement for MIUDELLA, a hormone-free copper IUD and the first such device approved in the U.S. in roughly 40 years.
The company has also completed the sale of its JADA System to Laborie Medical, refining its focus within reproductive and postpartum health.
For investors watching NYSE:OGN, these moves come as the stock trades around $7.51, with a 1-year return of a 51% decline and a 3-year return of a 64.5% decline. The recent...